Cardio-oncology study
Not Applicable
Not yet recruiting
- Conditions
- Circulatory SystemAnthracycline therapy related cardiac dysfunctionCardiology
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
age: 18 to 50 years
Cancer patients who received anthracycline therapy and developed subclinical ATRCD during follow up
Exclusion Criteria
Patient who is taking carvedilol
Patient who has any of the conditions:HT,DM,CKD,CAD
Patient who has low LVEF
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie anthracycline-induced cardiotoxicity in low-income settings?
How does early detection of subclinical cardiac dysfunction improve outcomes in anthracycline-treated patients?
Which biomarkers are most effective for predicting anthracycline-related cardiac toxicity in oncology?
What are the comparative effectiveness strategies for managing anthracycline cardiotoxicity in resource-limited regions?
How do combination therapies mitigate anthracycline-induced cardiac dysfunction while maintaining anti-tumor efficacy?